Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (THTX)
NASDAQ:THTX
Earnings Data
Report Date
Jul 10, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0Last Year’s EPS
0.02Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 09, 2025
|% Change Since: 25.16%
|Next Earnings Date:Jul 10, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and new product approval, indicating positive market momentum. However, challenges such as the drug shortage and declining Trogarzo sales were significant concerns. The company's strategic focus on transitioning to the new product formulation and managing operational efficiencies shows resilience.Company Guidance
During the Theratechnologies first quarter 2025 earnings call, the company reported total revenues of $19 million, reflecting a 17% growth from the same period last year. This growth was primarily driven by their lead asset, EGRIFTA SV, which experienced strong momentum in the market. Despite a temporary drug shortage that impacted sales for six to seven weeks, new enrollments were up by 15% compared to the previous year. The company's adjusted EBITDA for the quarter was positive at $2.3 million, a significant improvement from a loss of $247,000 in the same period last year. Theratechnologies provided guidance for 2025, expecting revenues between $80 million and $83 million and adjusted EBITDA ranging from $10 million to $12 million. The approval of their new F8 Formulation of Tesamorelin is anticipated to further bolster growth, with a planned transition from EGRIFTA SV to EGRIFTA WR to be completed by early 2026.Revenue Growth
Theratechnologies reported total revenues of $19 million for the fiscal first quarter, representing a 17% growth from the same period last year. The growth was primarily driven by EGRIFTA SV.
New Product Approval
The company received approval for the F8 Formulation of Tesamorelin, which only requires once-weekly reconstitution, a significant improvement over the previous daily requirement.
Increased Patient Enrollment
New enrollments were up 15% in the first quarter compared to last year, indicating strong market demand and effective sales strategies.
Adjusted EBITDA Improvement
The company reported a positive adjusted EBITDA of $2.3 million versus an adjusted EBITDA loss of $247,000 last year.
HIV Business Data Presentation
Data from the PROMISE-U.S. and VAMOS studies were presented, showcasing the efficacy and safety of ibalizumab in reducing HIV to undetectable levels in heavily treatment-experienced patients.
---
THTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
THTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 09, 2025 | $1.55 | $1.42 | -8.39% |
| Feb 26, 2025 | $1.82 | $1.60 | -12.09% |
| Oct 10, 2024 | $1.22 | $1.26 | +3.28% |
| Jul 10, 2024 | $1.55 | $1.50 | -3.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Theratechnologies Inc (THTX) report earnings?
Theratechnologies Inc (THTX) is schdueled to report earning on Jul 10, 2025, TBA Not Confirmed.
What is Theratechnologies Inc (THTX) earnings time?
Theratechnologies Inc (THTX) earnings time is at Jul 10, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is THTX EPS forecast?
THTX EPS forecast for the fiscal quarter 2025 (Q2) is 0.
---